BRAF and cutaneous melanoma: This benefit mostly manifested as stabilization of disease (in contrast to the rapid-onset major tumor regressions seen with mutant-BRAF inhibitors in cutaneous melanoma [34]) raising the speculation that it may have been mediated by mechanisms other than inhibition of the MAPK-pathway.